Remove Biosimilars Remove Documentation Remove Vaccines
article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108
article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

The document says that public funding for the development of vaccines and treatments should be more transparent, and include provisions to ensure that any resulting products are distributed evenly around the world. As of 2019, about 1.9 million people have type 1 diabetes in the U.S.,

Diabetes 236
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why most extractables & leachables studies fail regulatory review-and how to fix them

Express Pharma

Most projects fail not in the lab, but in study design, regulatory interpretation, and documentation. Real example: Injectable in a glass vial We supported a vaccine company using Type I glass vials they assumed were inert. The reason? Include Toxicological Justification: Work with a toxicologist to evaluate and qualify extractables.

article thumbnail

ICH Q6B for Analytics

PharmaTech

A magnifying glass examining a vintage vaccine vial surrounded by four minimalistic chart icons, symbolizing healthcare, medicine, and analytics in the context of global health monitoring. Biosimilars continue to build as a sector of this market with an estimated 2025 value in the region of US$42 billion (1).

Dosage 52
article thumbnail

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Pharmacy Times

They can collect documentation on prior preventive therapies, baseline MMDs, and follow-up outcomes to support prior authorization, including site-of-care arrangements. of participants discontinued due to adverse effects.

article thumbnail

Quality by design with a focus on biosimilars

Pharmaceutical Technology

QbD principles are woven into regulatory guidance documents, primarily guidances Q8 to Q11 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Practising QbD in biosimilar product development. For biosimilars, however, this process is slightly more complex.

article thumbnail

Research Suggests Vitamin D Deficiency Is a Risk Factor for Autism

Pharmacy Times

2 Evidence Supporting Supplementation A randomized controlled trial involving high-dose vitamin D (300 IU/kg/day, up to 5000 IU/day) in children with ASD documented meaningful improvements in Childhood Autism Rating Scale (CARS) scores, repetitive behaviors, eye contact, and attention after 4 months, without toxicity.